Palliative care is about support, comfort, symptom control and quality of life for people living with serious illness. That makes the medical cannabis question feel personal and urgent for some patients and carers. The safe answer is that cannabis-based medicines are not a general palliative-care promise, but they may come up in carefully reviewed specialist conversations where symptoms remain difficult and other options have not been enough or are unsuitable.
This guide is for patients, families and carers who want to understand the UK boundary before raising the subject. It is not medical advice, and it does not replace the palliative care team, oncology team, pain team, pharmacist, hospice team, GP surgery records route or specialist prescriber involved in a person’s care.
If you are trying to understand the wider UK route, start with the MCPH patient guide and how the UK medical cannabis prescription process works. For safety background, read medical cannabis side effects and medical cannabis and medication interactions.
The short answer
Medical cannabis should not be presented as a standard palliative care treatment. Palliative care covers many symptoms and many illnesses, and a cannabis-based medicine that is unsuitable for one person may be considered differently for another.
The clearest patient-safe framing is:
- palliative care decisions should stay with the specialist team looking after the patient;
- symptoms such as pain, nausea, appetite loss, anxiety, sleep problems or spasms need their own assessment;
- nabilone has a specific UK role for chemotherapy-induced nausea and vomiting, not for every palliative symptom;
- unlicensed cannabis-based medicinal products need specialist prescribing, risk review and monitoring;
- frailty, confusion, falls risk, sedation, interactions and impairment matter;
- diagnosis or stage of illness does not equal automatic qualification.
For carers, the practical question is often: “Who on the care team can review this safely?” rather than “Can we get cannabis?”
What palliative care means
NHS information describes end of life and palliative care as support for people with serious illness and those close to them. It can happen at home, in hospital, in a hospice or across several settings. It may sit alongside active treatment, or it may become the main focus when disease-directed treatment is no longer possible or no longer the priority.
Palliative care is not only about the final days of life. It can involve symptom control, emotional support, advance care planning, medicines review, mobility support, nutrition, family support and practical decisions about where care happens.
That breadth is why medical cannabis content needs a lower temperature here. A page cannot safely say that cannabis helps “palliative care” as if palliative care were one symptom or one diagnosis.
Where medical cannabis may enter the discussion
Patients and carers may ask about medical cannabis when symptoms remain difficult despite standard care, or when standard treatments cause side effects that are hard to tolerate. The conversation may involve pain, chemotherapy nausea, appetite symptoms, sleep, anxiety, spasms or general distress.
MCPH should not turn those questions into symptom-control promises. The better framing is that cannabis-based medicines may be one topic a specialist team can review as part of a wider plan.
That review should include:
- the main diagnosis and current stage of illness;
- which symptom is being discussed;
- what treatments have already been tried;
- what medicines are currently being used;
- whether Summary Care Record or GP surgery records are needed for a separate specialist assessment;
- whether the patient is becoming drowsy, confused, unsteady or dehydrated;
- whether a new symptom needs urgent assessment rather than a treatment trial;
- who would monitor benefit, side effects and stopping points.
If nabilone is being discussed, it should be tied to chemotherapy-induced nausea and vomiting and the NICE boundary around optimised conventional antiemetics. If an unlicensed cannabis-based medicinal product is being discussed, it should be treated as a specialist decision with limited evidence and a clear monitoring plan.
Why the palliative team boundary matters
People receiving palliative care may be taking several medicines at once. These can include opioids, anti-sickness medicines, steroids, antidepressants, antipsychotics, benzodiazepines, sleeping tablets, anticoagulants, chemotherapy medicines, immunotherapy, antibiotics, laxatives and medicines for breathlessness or seizures.
Cannabis-based medicines can add side effects such as sleepiness, dizziness, dry mouth, confusion, anxiety, mood changes, impaired attention and feeling unsteady. In someone who is frail, dehydrated, older, very tired or already taking sedating medicines, those effects can have a bigger impact.
The team boundary is not gatekeeping for its own sake. It is how clinicians check whether a new medicine might worsen falls risk, delirium, interactions, swallowing problems, constipation, impairment, anxiety, blood pressure, hydration or other care priorities.
What patients and carers can ask
Patients and carers are allowed to ask informed questions. A calm, practical conversation may include:
- Which symptom are we trying to review: pain, nausea, appetite, sleep, anxiety, spasms or something else?
- Have the usual palliative options for that symptom been reviewed recently?
- Is nabilone relevant, or is this a different kind of cannabis-based medicine discussion?
- What are the main risks in this person’s situation?
- Could this interact with current medicines or increase sleepiness, confusion or falls risk?
- If a trial is considered, what would count as enough benefit to continue?
- What side effects would mean stopping or urgent review?
- Who should the carer contact if symptoms change suddenly?
The aim is shared understanding. It should never become pressure on a clinician to prescribe, and it should never leave a carer managing a complex medicine without the team.
Urgent-care boundaries
Some symptoms in palliative care need quick clinical review. Do not treat a medical cannabis article as a replacement for urgent advice.
Use the care team’s urgent contact route, hospice advice line, oncology hotline, GP out-of-hours service, NHS 111, 999, or the locally advised route if there is sudden confusion, severe drowsiness, uncontrolled pain, severe breathlessness, repeated vomiting, dehydration, a fall, chest pain, a seizure, new weakness, suicidal thoughts, signs of infection, or any symptom the care team has told you is urgent.
If a person is already prescribed a cannabis-based medicine and becomes unsafe, heavily sedated, very confused or more breathless, treat that as a clinical review issue rather than trying to adjust anything privately.
Driving, work and daily safety
Some palliative patients still drive, work, care for others or manage medicines at home. THC-containing medicines can impair attention, reaction time and judgement. UK drug-driving law and medical-defence rules are separate from whether a medicine is prescribed. This article cannot give driving clearance.
For the general MCPH background, read medical cannabis and driving in the UK and THC side effects and impairment. The personal decision needs the prescriber and, where relevant, DVLA or specialist advice.
What this means in plain English
Palliative care is already specialist, human and practical. Medical cannabis can be part of a question, but it should not become the headline answer.
The safest next step is to name the symptom clearly, ask the palliative or oncology team whether any cannabis-based medicine has a place, and keep the review connected to the person’s full care plan. Benefit cannot be promised. Suitability is not automatic. Product, dose, route, monitoring and stopping decisions belong with the prescriber and the care team.
FAQ
Is medical cannabis routinely used in palliative care?
No. It should not be described as routine palliative care. Some specialist teams may discuss cannabis-based medicines in selected circumstances, but the decision depends on the symptom, evidence, risks, current medicines and monitoring plan.
Can it help appetite, pain or nausea at end of life?
This article does not make a general symptom-control claim. Nausea, appetite, pain and distress each need separate assessment. Nabilone has a specific place for chemotherapy-induced nausea and vomiting when conventional antiemetics have not controlled symptoms well enough; broader claims need specialist review.
Should carers raise medical cannabis with the hospice or palliative team?
Yes, if it is a real question for the patient or family, raise it openly with the team. The safer route is an honest medicines and symptom review, not a private decision made around the care team.
Does a palliative diagnosis make someone eligible?
No. A palliative care context does not automatically mean a person may qualify for a cannabis-based medicine. Suitability still depends on clinical assessment, records, previous treatments, risks, current medicines and the prescriber’s judgement.
Can this article suggest a product or dose?
No. Product, form, dose, route, titration, monitoring and stopping rules belong with the specialist prescriber and care team.
Sources
- NHS. Medical cannabis. https://www.nhs.uk/medicines/medical-cannabis/
- NHS. End of life care. https://www.nhs.uk/tests-and-treatments/end-of-life-care/
- NHS England. Palliative and end of life care. https://www.england.nhs.uk/eolc/
- NICE. Cannabis-based medicinal products: recommendations, NG144. https://www.nice.org.uk/guidance/ng144/chapter/recommendations
- NHS England. Cannabis-based products for medicinal use. https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/
- GMC. Information for doctors on cannabis-based products for medicinal use. https://www.gmc-uk.org/professional-standards/learning-materials/information-for-doctors-on-cannabis-based-products-for-medicinal-use
- CQC. Cannabis-based medicinal products: what CQC expects providers to know. https://www.cqc.org.uk/guidance-providers/healthcare/cannabis-based-medicinal-products-what-cqc-expects-providers
- GOV.UK. Drug driving law. https://www.gov.uk/drug-driving-law
Cover image brief: cover-brief.md.
